<DOC>
	<DOCNO>NCT00002346</DOCNO>
	<brief_summary>To study safety , tolerance , single multiple dose pharmacokinetics , anti-HIV activity bis-POM PMEA ( adefovir dipivoxil ) versus placebo administer orally daily basis 2 week HIV-infected patient .</brief_summary>
	<brief_title>The Safety Effectiveness Bis-POM PMEA HIV-Infected Patients</brief_title>
	<detailed_description>Patients randomize receive bis-POM PMEA one three fix dose level placebo daily 2 week . At dose level , nine patient receive bis-POM PMEA three patient receive placebo .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Prophylaxis aerosolize pentamidine , fluconazole , ketoconazole , trimethoprim/sulfamethoxazole , dapsone , provide stable regimen maintain least 4 week prior study entry . Patients must : HIV seropositivity . CD4 count &gt; = 100 cells/mm3 . p24 antigen ( immunecomplex dissociate ) &gt; = 50 pg/ml . Life expectancy least 6 month . Prior Medication : Allowed : Prior prophylaxis aerosolize pentamidine , fluconazole , ketoconazole , trimethoprim/sulfamethoxazole , dapsone . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active , serious infection ( HIV infection ) require parenteral antibiotic therapy . Malignancy cutaneous Kaposi 's sarcoma . Clinically significant cardiac disease , include symptom ischemia , congestive heart failure , arrhythmia . Gastrointestinal malabsorption syndrome . Inability take oral medication . Concurrent Medication : Excluded : Any parenteral antibiotic therapy . Diuretics . Amphotericin B. Didanosine ( ddI ) . Fluconazole . Foscarnet . Ganciclovir . Interferonalpha . Interferonbeta . Isoniazid . Aminoglycoside antibiotic . Ketoconazole ( topical allow ) . Itraconazole . Rifabutin . Rifampin . Stavudine ( d4T ) . Zalcitabine ( ddC ) . Zidovudine ( AZT ) . Lamivudine ( 3TC ) . Any investigational agent ( except sponsor approval ) . Systemic therapy Kaposi 's sarcoma . Patients follow prior condition exclude : History lactose intolerance . Prior Medication : Excluded within 2 week prior study entry : Any parenteral antibiotic therapy . Diuretics . Amphotericin B. Didanosine ( ddI ) . Fluconazole . Foscarnet . Ganciclovir . Interferonalpha . Interferonbeta . Isoniazid . Aminoglycoside antibiotic . Ketoconazole ( topical allow ) . Itraconazole . Rifabutin . Rifampin . Stavudine ( d4T ) . Zalcitabine ( ddC ) . Zidovudine ( AZT ) . Lamivudine ( 3TC ) . Any investigational agent ( except sponsor approval ) . Excluded within 4 week prior study entry : Systemic therapy Kaposi 's sarcoma . Active substance abuse ( include alcohol ) determine questionnaire positive drug screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 1995</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Adenine</keyword>
</DOC>